title: Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS.
abstract: Although low-dose methotrexate (MTX) has been used to treat several autoimmune diseases like lupus erythematosus, rheumatoid arthritis, etc., it has not yet been used to treat patients with primary antiphospholipid syndrome (PAPS). Parallel to clinical follow-up of female patient with a severe form of PAPS, antiphospholipid antibodies (aPL), blood coagulation, and hematological parameters in the peripheral blood have been monitored. MTX improved ulcers, livedo reticularis, decreased aPL titers, increased platelet counts, and improved blood coagulation parameters (e.g., factor VIII) and was well tolerated. Low-dose MTX was safe and effective in the presented case with PAPS. The clinical benefit may be due to the downregulation of increased aPL titers and amelioration of disturbed coagulation parameters.
authors.affiliation: Department of Radiology, University of Bonn, Sigmund-Freud Strasse 25, Bonn 53105, Germany. i.boehm@uni-bonn.de
authors.forename: Ingrid
authors.initials: I
authors.lastname: Boehm
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000187:drug effects* / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D016896:Treatment Outcome
chemical_list: D017152:Antibodies, Antiphospholipid; D007166:Immunosuppressive Agents; D008727:Methotrexate
references.citation: Rheumatol Int. 1998;18(2):59-62
references.pmid: 9782534
references.citation: J Thromb Haemost. 2006 Feb;4(2):295-306
references.pmid: 16420554
references.citation: JAMA. 2006 Mar 1;295(9):1050-7
references.pmid: 16507806
references.citation: Immunobiology. 2005;210(10):749-54
references.pmid: 16325493
references.citation: Front Biosci. 2007 May 01;12:3093-103
references.pmid: 17485284
references.citation: Biomed Pharmacother. 2003 Sep;57(7):278-81
references.pmid: 14499173
references.citation: Lupus. 2005;14(7):499-504
references.pmid: 16130503
references.citation: Ther Apher. 1998 May;2(2):157-9
references.pmid: 10225719
references.citation: J Rheumatol. 2008 Sep;35(9):1768-75
references.pmid: 18634157
references.citation: Arthritis Rheum. 2008 Sep;58(9):2824-34
references.pmid: 18759321
references.citation: Ann Hematol. 2006 Feb;85(2):134-5
references.pmid: 16292550